Shares of Moderna (NASDAQ: MRNA) jumped 7% on Monday after the biotech released positive data from a key clinical trial for its COVID-19 vaccine, mRNA-1273. Moderna said interim data from a phase 2/3 study suggested its vaccine demonstrated "a robust neutralizing antibody response" in kids aged 6 to 11 after two 50-microgram doses. Critically, the drug also demonstrated "a favorable safety profile."
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting